ArticleAtherosclerosis2022
Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA).
Article in Atherosclerosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.Circulation · 2025 · on this mapPooled it
- Omega-3 Polyunsaturated Fatty Acids are not associated with Peripheral Artery Disease in a Meta-Analysis from the Multi-Ethnic Study of Atherosclerosis and Atherosclerosis Risk in Communities Study Cohorts.The Journal of nutrition · 2024Pooled it
- Associations of lipoprotein(a) concentrations with cardiovascular disease in men and women with primary hypercholesterolemia.Atherosclerosis plus · 2026Article
- Two-Point Change Patterns of LDL-Cholesterol and hs-CRP and Risk of Major Adverse Cardiovascular Events in Middle-Aged and Older Chinese Adults: A Prospective Cohort Study.Health science reports · 2026Article
- Correlation between serum and plasma lipoprotein(a) measurements: ARIC study.Journal of clinical lipidology · 2026Article
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Association Between Lipoprotein(a) Testing, Lipid-Lowering Therapy Intensification, and Low-Density Lipoprotein Cholesterol Goal Attainment: Findings From the Veterans Affairs Health System.Journal of the American Heart Association · 2026Article
- Senescence protein signatures predict dementia risk with causal implication for TBCA: a two-cohort study.Research square · 2026Article
- Lipoprotein(a) Lowering with Pelacarsen (TQJ230).Cardiovascular & hematological disorders drug targets · 2026Review
- Time in LDL cholesterol target range and major adverse cardiovascular events risk: A pooled analysis of two cohorts.American journal of preventive cardiology · 2025Article
- Evolving strategies in cardiovascular disease prevention: 2025 American society for preventive cardiology highlights.American journal of preventive cardiology · 2025Review
- Hunting for a coronary artery disease diagnosis in asymptomatic patients with diabetes mellitus: if, how and when.Cardiovascular diabetology · 2025Review
- Identification and management of patients at high-risk for cardiovascular disease in primary prevention.American journal of preventive cardiology · 2025Review
- Lipoprotein (a) in primary cardiovascular disease prevention is actionable today.American heart journal plus : cardiology research and practice · 2025Review
- Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications.Diabetes, obesity & metabolism · 2025Review
- Lipoprotein(a) and coronary artery disease: The need for universal screening - A case-based review.American heart journal plus : cardiology research and practice · 2025Review
- Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature.Biomolecules · 2025Review
- Prevalence of Lp(a) in a real-world Portuguese cohort: implications for cardiovascular risk assessment.Lipids in health and disease · 2025Article
- The Association of Lipoprotein(a) Levels with Atherosclerotic Cardiovascular Disease in Thailand: A Cross-Sectional Study.Vascular health and risk management · 2025Article
- Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications.Current medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsPlasma low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) are both associated with coronary heart disease (CHD). This study investigated whether elevated plasma Lp(a) concentration was associated with increased CHD risk when LDL-C was low (≤100 mg/dL) in individuals not on statin therapy.
methodsParticipants from the Multi-Ethnic Study of Atherosclerosis (MESA) (n = 4,585) were categorized into four groups: Group 1: LDL-C ≤ 100 mg/dL, Lp(a) < 50 mg/dL; Group 2: LDL-C > 100 mg/dL, Lp(a) < 50 mg/dL; Group 3: LDL-C ≤ 100 mg/dL, Lp(a) ≥ 50 mg/dL; and Group 4: LDL-C > 100 mg/dL, Lp(a) ≥ 50 mg/dL. The relationship of Lp(a) and LDL-C with time to CHD events was assessed with Kaplan Meier curves and multivariable Cox proportional hazard models.
resultsParticipants were followed for a mean of 13.4 years and a total of 315 CHD events occurred. Compared to participants with LDL-C ≤ 100 mg/dL and Lp(a) < 50 mg/dL, those with LDL-C > 100 mg/dL and Lp(a) < 50 mg/dL (Group 2) demonstrated no increased risk for CHD events (HR: 0.92; 95% CI: 0.69, 1.21). However, participants with LDL-C ≤ 100 mg/dL and Lp(a) ≥ 50 mg/dL (Group 3) and those with LDL-C > 100 mg/dL and Lp(a) ≥ 50 mg/dL (Group 4) exhibited significantly increased risk of CHD events compared to Group 1 (HR: 1.83; 95% CI: 1.02, 3.27) and Group 2 (HR: 1.61; 95% CI: 1.15, 2.26), respectively.
conclusionsWhen Lp(a) was elevated, risk of CHD events increased, regardless of baseline LDL-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.